O3 Holding GmbH (the Company), the holding company of KD Pharma Group, announces today the appointment of Manja Boerman as Chief Executive Officer of KD Pharma Group, effective August 24, 2026.

O3 Holding GmbH (the Company), the holding company of KD Pharma Group, announces today that Oscar Groet, Chief Executive Officer of KD Pharma Group has decided to step down from his role as CEO.

The expansion of our Centre of Excellence for softgels manufacturing in Miami, USA, with the addition of a 6th manufacturing line, further enhances the site’s production capacity and operational flexibility.

O3 Holding GmbH – Acquisition of the distribution and supply business for food grade oils from dsm-firmenich, financed by a shareholder loan

KD LabService has once again been awarded the GOED Special Achievement Program (SAP) recognition for 2025–2026.

We are delighted to announce the launch of our global cross-company audit initiative, a key step toward harmonizing practices across the KD Pharma Group.

Our QC teams in Bexbach, Germany and in Mulgrave, Canada, achieved first and second place in the AOCS Laboratory Proficiency Program for GOED Nutraceutical Oils.

The transaction expands KD Pharma Group‘s lipids CDMO business and includes the MEG-3® fish oil omega-3 product portfolio and two associated production sites in Canada and Peru

We are delighted to announce the collaboration between KD Pharma Group and DUDE CHEM, a fast growing deeptech company specialized in green chemistry manufacturing, for an impactful digitalization pilot project.